Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Proteomics International Laboratories Ltd

ABN

78 169 979 971

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- Class of *securities issued or to be issued
- a. Shares.b. Options.
- 2 Number of *securities issued or to be issued (if known) or maximum number which may be issued
- Principal of the terms 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- a. 1,436,171 Shares.b. 500,000 Tranche 2 Consultant Options.
- a. Fully paid ordinary shares (Shares).
- b. Options exercisable at \$0.35 each on or before 8 March 2020 (**Tranche 2 Consultant Options**).

⁺ See chapter 19 for defined terms.

- Do the +securities rank equally Yes. 4 a. in all respects from the +issue b. No. Options over unissued shares date with an existing +class of may only be exercised in accordance quoted +securities? with the terms and conditions. Upon conversion of the options to If the additional +securities do shares, the shares will rank equally not rank equally, please state: with existing shares. the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration \$0.20 per Share. 5 a. b. Nil. Purpose of the issue 6 Exercise of listed options at \$0.20 a. (If issued as consideration for each expiring on 31 March 2018. the acquisition of assets, clearly b. Options issued to a consultant as identify those assets) part consideration for services rendered. Is the entity an +eligible entity No. 6a that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b -6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder Not applicable. resolution under rule 7.1A was
 - 6c Number of *securities issued without security holder approval under rule 7.1

500,000 Tranche 2 Consultant Options.

passed

⁺ See chapter 19 for defined terms.

- 6d Number of *securities issued with security holder approval under rule 7.1A
- 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.
- 6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable) Nil.

Nil.

1,436,171 Shares

Not applicable.

Not applicable.

7.1: 4,150,585

7.1A: Not applicable.

a. 8 March 2018.

b. 8 March 2018.

Number+Class64,994,236Fully paid ordinary
shares.15,104,635Options exercisable
at \$0.20 each on or
before 31 March
2018.

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	95	Performance Rights with nil exercise price, each vests into 100,000 shares subject to specific vesting conditions and a vesting cap.
		500,000	Consultant Options exercisable at \$0.25 each on or before 17 July 2019.
		650,000	Employee Options exercisable at \$0.30 each on or before 31 October 2019.
		500,000	Consultant Options exercisable at \$0.35 each on or before 8 March 2020.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable.

Part 2 - Pro rata issue

Questions 11 to 33 – Not Applicable

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of *securities (*tick one*)
- (a) +Securities described in Part 1

*In respect of shares issued on exercise of PIQO Options

(b) All other ⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

⁺ See chapter 19 for defined terms.

Questions 35 to 37 - Not Applicable

Entities that have ticked box 34(b)

Questions 38 to 42 – Not Applicable.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:		Date: 8 March 2018
C	Company Secretary	
Print name:		
	Karen Logan	
== == == == ==		

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	58,998,710			
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid ⁺ordinary securities cancelled during that 12 month 	 2,127,221 556,250 fully paid ordinary shares issued 5 February 2018, exception 4. 134,800 fully paid ordinary shares issued 15 February 2018, exception 4. 1,436,171 fully paid ordinary shares issued 8 March 2018, exception 4. Nil 			
period	61,125,931			

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"					
"В"	0.15 [Note: this value cannot be changed] 9,168,890				
<i>Multiply</i> "A" by 0.15					
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used					
 Insert number of ⁺equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate 	 shares issued on 5 March 2018. 500,000 options issued on 8 March 2018, exercisable at \$0.35 each on or before 8 March 2020. 				
line items					
•	5,018,305				
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1					
"A" x 0.15	9,168,890				
Note: number must be same as shown in Step 2					
Subtract "C"	5,018,305				
Note: number must be same as shown in Step 3					

[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
" A "	Not applicable			
Note: number must be same as shown in Step 1 of Part 1				
Step 2: Calculate 10% of "A"				
"D"	0.10			
	Note: this value cannot be changed			
<i>Multiply</i> "A" by 0.10	Not applicable			
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule			
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Not applicable			
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 				
"E"	Not applicable			
Step 4: Subtract "E" from ["A" x "E placement capacity under rule 7.1A				
"A" x 0.10	Not applicable			
Note: number must be same as shown in Step 2				
Subtract "E"	Not applicable			

⁺ See chapter 19 for defined terms.

Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	Not applicable
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.